SCHEDULE: JPMorgan Discloses 5.2% Stake in Neurocrine Biosciences

JPMorgan Chase & Co. has reported a 5.2% beneficial ownership stake in Neurocrine Biosciences, Inc. as of December 31, 2025, held in the ordinary course of business.

Summary

• JPMorgan Chase & Co. has filed a Schedule 13G, disclosing its beneficial ownership in Neurocrine Biosciences, Inc.
• As of December 31, 2025, JPMorgan beneficially owned 5,198,084 shares of Neurocrine Biosciences' Common Stock.
• This represents 5.2% of the total class of securities outstanding.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• JPMorgan's sole voting power covers 4,705,046 shares, while shared voting power is 21,535 shares.
• Sole dispositive power is held over 5,196,778 shares, and shared dispositive power over 1,221 shares.
• The filing was made by JPMorgan as a parent holding company, with several subsidiaries identified as acquiring entities, including J.P. Morgan Trust Company of Delaware and J.P. Morgan Securities LLC.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant institutional stake, which is generally a positive signal of investor confidence, but it does not provide new operational or financial performance information to significantly alter sentiment.

Positives

• Significant institutional investment from a major financial institution like JPMorgan Chase & Co. indicates confidence in Neurocrine Biosciences.
• The holding is for investment purposes in the ordinary course of business, suggesting a long-term, passive investment strategy rather than an activist one.

Negatives

• No specific negative information is contained within this beneficial ownership disclosure.

Risks

• No specific risks related to Neurocrine Biosciences are mentioned in this filing, as it is a disclosure of ownership, not a company financial report.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Neurocrine Biosciences' future performance or operations.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors who acquire more than 5% of a company's stock for passive investment purposes. JPMorgan's stake in Neurocrine Biosciences reflects a large financial institution's investment in the biotechnology sector, a common practice for diversified portfolios seeking exposure to growth industries.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by JPMorgan Chase & Co. may be viewed positively, potentially signaling institutional confidence in Neurocrine Biosciences.
• Company Management: Awareness of a major institutional investor holding a significant stake may influence strategic decisions, though JPMorgan's filing indicates a passive investment.

Key Dates

Keywords

Neurocrine Biosciences, JPMorgan Chase, NBIX, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals